The Benchmark Company initiated coverage on Kamada with a new price target
$KMDA
Biotechnology: Pharmaceutical Preparations
Health Care
The Benchmark Company initiated coverage of Kamada with a rating of Buy and set a new price target of $15.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/21/2025 | $15.00 | Buy | The Benchmark Company |
| 7/3/2024 | $18.00 | Buy | Stifel |
The Benchmark Company initiated coverage of Kamada with a rating of Buy and set a new price target of $15.00
Stifel initiated coverage of Kamada with a rating of Buy and set a new price target of $18.00
Funding Strengthens Kamada's Financial Position, Supporting its Growth Plans and the Pursuit of Strategic Business Development OpportunitiesAppointment of Two New Independent Directors to its Board: Professor Benjamin Dekel and Mr. Assaf Itshayek REHOVOT, Israel and HOBOKEN, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced shareholder approval and planned closing of the previously announced $60 million private placement (the "Private Placement") with FIMI Op
REHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))) ("Kamada" or the "Company"), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that following the recently announced $60 million private placement with the FIMI Opportunity Funds, which is expected to contribute to accelerating the growth of its existing business and allow the Company to pursue compelling business development opportunities, Chief Financial Officer (CFO), Chaime Orlev, who had previously planned to transition out of h
REHOVOT, Israel and HOBOKEN, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the "Ruling") from the Israel Tax Authority (the "ITA") with respect to the special cash dividend of $0.20 (approximately NIS 0.72) per share on the Company's ordinary shares (totaling approximately $11.5 million) announced on March 5, 2025 (the "Dividend"), expected to be paid on April 7, 2025 (the "Payment Date"), to shareholders of record at the close of busines
New Plasma Collection Center in San Antonio has Planned Annual Collection Capacity of Approximately 50,000 Liters Center Will Collect Normal Source Plasma and Specialty Plasma, such as Anti-Rabies and Anti-DSpecialty Plasma Collected will Support the Company's Increasing Demand for Hyper-Immune Plasma, and is Expected to Lower Raw Material CostsExpected Annual Revenue Contribution from Sales of Normal Source Plasma is Estimated at $8 Million to $10 Million at Full CapacityNew Center Opening Furthers Kamada's Growth Strategy REHOVOT, Israel and HOBOKEN, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio o
Record Year with Total 2024 Revenues of $161.0 Million, Representing a 13% Increase over Fiscal Year 2023 and Adjusted EBITDA of $34.1 Million, Up 42% Year-over-Year, and a 21% Margin of RevenuesCash Provided by Operating Activities of $47.6 Million During 2024 Resulted in a Year-End Strong Cash Balance of $78.4 Million; Solid Financial Position to Accelerate Inorganic Growth Net Income for the Year was $14.5 Million, or $0.25 per Diluted Share, Up 75% Year-over-YearStrong Performance Positions Company for Double Digit Profitable Growth in Fiscal Year 2025; Reiterates 2025 Full-Year Revenue Guidance of $178 Million to $182 Million and Adjusted EBITDA of $38 Million to $42 MillionDeclares Spe
REHOVOT, Israel and HOBOKEN, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the "Ruling") from the Israel Tax Authority (the "ITA") with respect to the special cash dividend of $0.20 (approximately NIS 0.72) per share on the Company's ordinary shares (totaling approximately $11.5 million) announced on March 5, 2025 (the "Dividend"), expected to be paid on April 7, 2025 (the "Payment Date"), to shareholders of record at the close of busines
Record Year with Total 2024 Revenues of $161.0 Million, Representing a 13% Increase over Fiscal Year 2023 and Adjusted EBITDA of $34.1 Million, Up 42% Year-over-Year, and a 21% Margin of RevenuesCash Provided by Operating Activities of $47.6 Million During 2024 Resulted in a Year-End Strong Cash Balance of $78.4 Million; Solid Financial Position to Accelerate Inorganic Growth Net Income for the Year was $14.5 Million, or $0.25 per Diluted Share, Up 75% Year-over-YearStrong Performance Positions Company for Double Digit Profitable Growth in Fiscal Year 2025; Reiterates 2025 Full-Year Revenue Guidance of $178 Million to $182 Million and Adjusted EBITDA of $38 Million to $42 MillionDeclares Spe
REHOVOT, Israel, and HOBOKEN, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that its Board of Directors has declared a special cash dividend of $0.20 (approximately NIS0.72) per share on the Company's ordinary shares (totaling approximately $11.5 million). The special cash dividend will be payable on April 7, 2025, to shareholders of record at the close of business on March 17, 2025. "Based on the Company's strong financial results for 2024 and its solid
6-K - KAMADA LTD (0001567529) (Filer)
6-K - KAMADA LTD (0001567529) (Filer)
SCHEDULE 13G/A - KAMADA LTD (0001567529) (Subject)
SC 13G/A - KAMADA LTD (0001567529) (Subject)
SC 13G/A - KAMADA LTD (0001567529) (Subject)
SC 13G/A - KAMADA LTD (0001567529) (Subject)